Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia

NCT07052006 is registered in ClinicalTrials.gov with Halia Therapeutics, Inc. as lead sponsor.

NCT NCT07052006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07052006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia
Lead sponsor
Halia Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 9, 2023
Completion date
October 15, 2026
Enrollment
37 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anemia in myelodysplastic syndromes, myelodysplastic syndrome